6.78

1.50% 0.10

Gyre Therapeutics Inc (GYRE)

Overview News Price History Why GYRE Down? Discussions Forecast

Gyre Therapeutics Inc stock is traded at $6.78, with a volume of 30,463. It is up +1.50% in the last 24 hours and up +12.07% over the past month. Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Previous Close:

$6.68

Open:

$6.62

24h Volume:

30,463

Relative Volume:

0.34

Market Cap:

$718.91M

Revenue:

$117.05M

Net Income/Loss:

$-3.71M

P/E Ratio:

-87.03

EPS:

-0.0779

Net Cash Flow:

$1.67M

1W Performance:

+0.89%

1M Performance:

+12.07%

6M Performance:

-17.42%

1Y Performance:

-16.71%

1-Day Range:

$6.60

$6.83

1-Week Range:

$6.44

$6.99

52-Week Range:

$5.44

$9.42

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name

Gyre Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(858) 284-0115

Address

12730 HIGH BLUFF DRIVE, SAN DIEGO

Employee

618

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

GYRE's Discussions on Twitter

Compare GYRE vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GYRE Gyre Therapeutics Inc	6.78	708.31M	117.05M	-3.71M	1.67M	-0.0779
VRTX Vertex Pharmaceuticals Inc	516.25	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.82	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.77	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.15	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.23	39.31B	5.76B	514.49M	1.10B	4.4813

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	Jefferies	Buy
Aug-26-25	Initiated	H.C. Wainwright	Buy
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Apr-29-21	Resumed	Stephens	Overweight
Feb-10-21	Initiated	Piper Sandler	Overweight
May-21-20	Initiated	Raymond James	Outperform
Jan-04-19	Initiated	Oppenheimer	Outperform
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy
Feb-09-18	Reiterated	Chardan Capital Markets	Buy
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy
Jun-12-17	Initiated	Chardan Capital Markets	Buy
Jun-06-17	Initiated	Ladenburg Thalmann	Buy
Jun-30-16	Initiated	Rodman & Renshaw	Buy

View All

Gyre Therapeutics Inc Stock (GYRE) Latest News

Aug 11, 2026

Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail

Aug 11, 2026

Aug 10, 2026

Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Aug 10, 2026

Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026